BIOA - BioAge Labs Debt to Book Capitalization Ratio

The liquidity reserve following the IPO guarantees the financial stability of BioAge Labs, Inc. (BIOA), while operating expenses and trial participant recruitment rates remain under strict control, with the metric standing at 0.01. The current market quotes visualized below help track the price action of this biopharmaceutical network, which leverages AI for aging analysis and the creation of a closed-loop R&D cycle. The business relies on ESG principles, implementing resource-saving and zero-waste synthesis methods within its laboratories.

BIOA (BioAge Labs, Inc) Debt to Book Value history from 09/27/2024 to 10/27/2026

BioAge Labs (BIOA) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price BioAge Labs, Inc.|BIOA - Analyst Consensus Forecast

- market capitalization data:

Market Value BioAge Labs, Inc|BIOA - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share BioAge Labs, Inc.|BIOA - Company Net Assets|Market Capitalization to Book Value Ratio bioagelabs.com|BIOA - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio BioAge Labs, Inc.|BIOA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity BioAge Labs Inc.|BIOA - Company Total Debt|Debts to Book Capitalization BioAge Labs, Inc

Fundamental company analysis:BioAge Labs, Inc. - BIOA

BioAge Labs, Inc. (BIOA) invests in the development of anti-aging and metabolic disorder drugs, which requires significant capital for clinical trials. The company's debt-to-book capitalization ratio measures the proportion of debt obligations relative to total asset value, allowing investors to assess financial stability and default risk through an analysis of the company's debt-to-book capitalization.

Competitors of BioAge Labs, Inc. (BIOA)